|
|
 Previous Article | Table of Contents | Next Article 
Blood, 1 January 2003, Vol. 101, No. 1, pp. 253-258
IMMUNOBIOLOGY
Mac-1 (CD11b/CD18) is crucial for effective Fc
receptor-mediated immunity to melanoma
Annemiek B. van Spriel,
Heidi H. van Ojik,
Annie Bakker,
Marco J. H. Jansen, and
Jan G. J. van de
Winkel
From the Immunotherapy Laboratory, Department of
Immunology, Department of Internal Medicine and Oncology, Medarex
Europe, and Genmab, University Medical Center Utrecht, The
Netherlands.
Antibody-reliant destruction of tumor cells by immune effector
cells is mediated by antibody-dependent cellular cytotoxicity, in
which Fc receptor (FcR) engagement is crucial. This study documents an
important role for the  2 integrin Mac-1 (CD11b/CD18) in
FcR-mediated protection against melanoma. CD11b-deficient mice,
those that lack Mac-1, were less protected by melanoma-specific
monoclonal antibody TA99 than wild-type (WT) mice. Significantly
more lung metastases and higher tumor loads were observed in
Mac-1 / mice. Histologic analyses revealed no
differences in neutrophil infiltration of lung tumors between
Mac-1/ and WT mice. Importantly, Mac-1/
phagocytes retained the capacity to bind tumor cells, implying that
Mac-1 is essential during actual FcR-mediated cytotoxicity. In summary,
this study documents Mac-1 to be required for FcR-mediated antimelanoma
immunity in vivo and, furthermore, supports a role for neutrophils
in melanoma rejection.
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
S. N. Karagiannis, M. G. Bracher, J. Hunt, N. McCloskey, R. L. Beavil, A. J. Beavil, D. J. Fear, R. G. Thompson, N. East, F. Burke, et al.
IgE-Antibody-Dependent Immunotherapy of Solid Tumors: Cytotoxic and Phagocytic Mechanisms of Eradication of Ovarian Cancer Cells
J. Immunol.,
September 1, 2007;
179(5):
2832 - 2843.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
V. D'Arcy, Z. K. Abdullaev, N. Pore, F. Docquier, V. Torrano, I. Chernukhin, M. Smart, D. Farrar, M. Metodiev, N. Fernandez, et al.
The Potential of BORIS Detected in the Leukocytes of Breast Cancer Patients as an Early Marker of Tumorigenesis.
Clin. Cancer Res.,
October 15, 2006;
12(20):
5978 - 5986.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
L. Bevaart, M. J.H. Jansen, M. J. van Vugt, J. S. Verbeek, J. G.J. van de Winkel, and J. H.W. Leusen
The High-Affinity IgG Receptor, Fc{gamma}RI, Plays a Central Role in Antibody Therapy of Experimental Melanoma
Cancer Res.,
February 1, 2006;
66(3):
1261 - 1264.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
M. Imai, C. Landen, R. Ohta, N.-K. V. Cheung, and S. Tomlinson
Complement-Mediated Mechanisms in Anti-GD2 Monoclonal Antibody Therapy of Murine Metastatic Cancer
Cancer Res.,
November 15, 2005;
65(22):
10562 - 10568.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K. Takeda, N. Yamaguchi, H. Akiba, Y. Kojima, Y. Hayakawa, J. E. Tanner, T. J. Sayers, N. Seki, K. Okumura, H. Yagita, et al.
Induction of Tumor-specific T Cell Immunity by Anti-DR5 Antibody Therapy
J. Exp. Med.,
February 17, 2004;
199(4):
437 - 448.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
F. Hong, R. D. Hansen, J. Yan, D. J. Allendorf, J. T. Baran, G. R. Ostroff, and G. D. Ross
{beta}-Glucan Functions as an Adjuvant for Monoclonal Antibody Immunotherapy by Recruiting Tumoricidal Granulocytes as Killer Cells
Cancer Res.,
December 15, 2003;
63(24):
9023 - 9031.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
C. F. Eisenbeis, M. A. Caligiuri, and J. C. Byrd
Rituximab: Converging Mechanisms of Action in Non-Hodgkin's Lymphoma?
Clin. Cancer Res.,
December 1, 2003;
9(16):
5810 - 5812.
[Full Text]
[PDF]
|
|
|
|
|
|
|
N. Di Gaetano, E. Cittera, R. Nota, A. Vecchi, V. Grieco, E. Scanziani, M. Botto, M. Introna, and J. Golay
Complement Activation Determines the Therapeutic Activity of Rituximab In Vivo
J. Immunol.,
August 1, 2003;
171(3):
1581 - 1587.
[Abstract]
[Full Text]
[PDF]
|
|
|
| |
